Myocardial fibrosis and glycolysis: a bibliometric study and visualization analysis (2000-2024)
Abstract
Background: Myocardial fibrosis represents a terminal pathological outcome in numerous cardiovascular diseases and is mechanistically linked to glycolytic dysregulation. However, systematic reviews integrating multidimensional evidence remain scarce.
Objective: This study aims to conduct a visual analysis of myocardial fibrosis and glycolysis research using CiteSpace and VOSviewer, quantifying research trends and key contributors.
Methods: Literature on "myocardial fibrosis" and "glycolysis" published between January 1, 2000, and December 31, 2024, was retrieved from the Web of Science, PubMed, and Scopus databases. After deduplication, 408 articles were included for analysis. CiteSpace and VOSviewer were employed to analyze data regarding countries, institutions, authors, and keywords.
Results: A total of 408 studies were included. Annual publications on myocardial fibrosis and glycolysis exhibited a fluctuating upward trend, increasing from 1 (2000) to 51 (2024). These publications were divided into three phases: Initial Exploration (2000-2003, 1 article per year), Slow Fluctuation (2004-2009, 3-5 articles per year), and Rapid Development (2010-2024). During the Rapid Development phase, publications surged from 25 in 2019 to 44 in 2020, peaked in 2021-2022 (45 and 48 articles, respectively), and rebounded to 51 in 2024. Key contributors: The U.S. (177 studies, 32% of global output) and China (115 studies, 20%) were the leading contributors, collectively accounting for 52%…
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.